licensingNovartis signs up to $1.9bn deal to tap Antares’ undruggable-target engineNovartis has signed a multi-target oncology discovery deal with Antares Therapeutics, paying $105m upfront for access to the Boston biotech’s small-molecule discovery engine. The agreement could bring … more ➔
fundraisingLeyden Labs adds €40m for intranasal flu preventionDutch biotech Leyden Labs has raised €40m from a group of investors to advance its nasal spray approach for protection against influenza and other respiratory viruses. more ➔
fundraisingRQ Bio raises $115m for long-acting flu antibodyLondon’s RQ Bio, a private biotech developing long-acting antibody therapeutics to prevent flu, has raised $115 million (£85.5 million/€101 million) in its Series A financing. more ➔
M&AThalia buys Sanmirna, becomes a clinical-stage RNA companyThalia Therapeutics is acquiring Sanmirna Therapeutics for an initial £3.675 million and up to £13 million in milestone payments, adding the clinical-stage acute myeloid leukemia (AML) candidate miRisten … more ➔
Start-upMerck launches build-to-buy Saturnus Bio with $50mMerck KGaA has partnered with Versant Ventures to launch Saturnus Bio, a new biotech developing precision medicines for rare genetic cardiomyopathies. more ➔
Start-upTRIMTECH extends seed round to $47M for protein degradation drugsUK-based TRIMTECH Therapeutics has raised an additional $14 million, bringing its total seed financing to $47 million. more ➔
Market accessAfter FDA rejection, Sanofi’s BTK inhibitor wins EU approvalSanofi’s Cenrifki (tolebrutinib) has been approved in the EU as the first disability-targeting medicine for adults with secondary progressive multiple sclerosis (SPMS) without relapses in the previous … more ➔
M&ACan Sanofi buy its way into in vivo CAR-T?Recent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from … more ➔
Start-upBionyra launches with $165m, France’s largest biotech Series AWith an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year … more ➔
licensingBioArctic signs potential $1bn Alzheimers research deal with Eli LillyBioArctic AB has signed a research and collaboration agreement with Eli Lilly potentially worth $1 billion, researching a new treatment combining BioArctic’s proprietary BrainTransporter technology with … more ➔
